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Chapter 1 General Introduction
General introduction
Alzheimer’s disease was first reported by the German neuropathologist Alois Alzheimer in 
1906, which explains the name of the disease. Alzheimer’s disease (AD) is an incurable neu-
rodegenerative disease that at present affects more than 25 million people worldwide, mostly 
people over 65 years old (Castellani et al., 2010). In the Netherlands, the number of people 
suffering from AD was 170,000 in the year 2000 and is estimated to be almost 500,000 in 2050, 
which for a small country corresponds to a high number of cases (Kümpers et al., 2006).  
AD is the seventh leading cause of death in the United States of America (USA) and is 
virtually tied with the sixth leading cause of death diabetes (Alzheimer’s association, 2010). In 
the USA, AD prevalence was estimated to five million persons in 2007 and is projected to 
increase to thirteen million in 2050. Furthermore, the number of AD patients and other de-
mentias in the USA is increasing every year due to the growth of the older population (Alz-
heimer’s association, 2010). This number will continue to increase and can escalate rapidly in 
the coming years as the “baby boom generation” ages. 
Many studies focus on improving the quality of life for AD patients. These studies are 
partly based on different hypotheses on the causes of AD, that are the cholinergic, the 
amyloid, the tau and the excitotoxicity hypothesis (degenerative cascade). 
The cholinergic hypothesis states that AD is caused by a decrease of the cholinergic 
neurotransmission which in turn is caused by a shortage of acetylcholine, an important 
chemical messenger for learning- and memory- processes. The degradation of acetylcholine 
into choline and acetic acid is catalyzed by the enzyme acetylcholinesterase (AChE) (Auter-
hoff and Hamacher) that is present in the synapse between the nerves. Various anti-AD drugs 
that are available in the market inhibit AChE and thereby slow down the worsening of the 
symptoms caused by AD. By inhibiting AChE, the level of acetylcholine rises resulting in an 
increased cognition between the neurons (Sugimoto, 2008). 
The amyloid hypothesis was proposed in the early 90s, and its essence is that the increased 
production or decreased clearance of Aβ peptides causes the disease. Accumulation of the 
Aβ40 and Aβ42 peptides results in aggregation and formation of insoluble plaques, which 
trigger a cascade of deleterious changes, resulting in neuronal death and thus causing AD. 
Overtime this hypothesis has undergone alterations due to facts that did not correlated well 
with some findings, as cases of AD patients with severely impaired memory showed no plaques 
at post-mortem analysis (Pimplikar, 2009). Furthermore recent advances in neuroimaging 
techniques in vivo have shown the presence of robust plaques in otherwise cognitively normal 
people (Villemagne et al., 2008). These observations have led to thinking that perhaps the 
insoluble plaques does not trigger the pathological events, and may be benign or even protec-
tive in nature (Pimplikar, 2009). There are also observations that Aβ accumulates intracel-
lularly in mouse models of AD and in human AD brains and could contribute to disease 
progression (LaFerla et al., 2007). Although the amyloid hypothesis remains the best defined 
and more widely accepted view, the evidence that Aβ causes the disease is not as strong as the 
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supporters would like to believe and for those who believe the amyloid hypothesis to be 
completely wrong do not have data to support such a claim (Pimplikar, 2009).   
The tau hypothesis is based on the concept that hyperphosphorylation of the tau protein con-
stitutes a final common pathway in AD. These hyperphosphorylated tau oligomers exert patho-
logical effects, triggering neurotoxic actions that affect the normal interaction patterns of the 
neuronal cytoskeleton, which seems to correlate with cognitive impairment (Maccioni et al., 2010). 
The excitotoxicity hypothesis has been extensively investigated for a variety of neurodegen-
erative diseases. Excitotoxicity is a neuron degeneration caused by excessive exposure to ex-
citatory amino acids (EAA). L-glutamate is an EAA and has been identified as the principal 
transmitter mediating fast excitatory synaptic responses in the vertebrate central nervous 
system (CNS) (Collingridge and Lester, 1989). Glutamate receptors are divided on the basis of 
their mode of action and pharmacological properties into two major subdivisions: ionotropic 
channel receptors (iGluR) and metabotropic G-protein coupled receptors (mGluR). iGluRs 
are characterized by their selective affinity for specific agonists: N-methyl-D-aspartate (NMDA), 
α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid and kainic acid (Hynd et al., 2004). 
NMDA receptors constitute a major class of Glu receptors in the mammalian CNS (MacDon-
ald et al., 1989), and can mediate post-synaptic Ca2+ influx. Koh and Choi performed in vitro 
experiments and showed that the accumulation of radio labeled Ca2+ correlates closely with 
the degenerative process, suggesting that the toxicity is principally mediated by Ca2+ influx 
probably via NMDA receptors (Koh and Choi, 1991). Memantine, the drug targeting this 
mechanism, acts as a NMDA antagonist. It improves the signal-to-noise ratio of glutamatergic 
transmission and protects cortical neurons from the toxic effects of chronic over exposition to 
glutamate (Parson et al., 2007). 
AD is one of the human disorders that have triggered the largest number of hypotheses to 
explain its pathogenesis, probably by the fact that no cure has yet been found for this devastat-
ing disease. Other hypotheses which are not outlined here, such as oxidative stress (Praticò, 
2008) and metal hypothesis (Bush and Tanzi, 2008) are also under investigation to find new 
treatment possibilities and biomarkers for an early recognition of AD (Khan and Alkon, 2010, 
Nichols et al., 2006, Trojanowski et al., 2010).     Most of the anti-AD drugs currently available 
on the market (galantamine, donepezil and rivastigmine) are based on the cholinergic hypoth-
esis. Memantine is the only drug targeting NMDA receptors. Further on, it is the only substance 
registered for the treatment of moderate to severe AD patients (Parsons et al., 2007).
Enormous amounts of potential drug candidates are discovered and synthesized in today’s 
drug discovery campaigns (Ali et al., 2010, Bolognesi et al., 2003, Korabecny et al., 2010). Sci-
entists search for compounds which present higher potencies with new modes of action and 
better toleration. Huperzine A, an alkaloid isolated from Huperzia serrata, can be named as a 
recent successful example in the context of AD. Huperzine A is entering phase II clinical trials 
in the USA and is already being used for AD treatment in China, since 1996 (Ma et al., 2007). 
The development of drug candidates consists of four distinct stages: 1) drug discovery, 2) 
preclinical development; 3) clinical development; and 4) manufacturing. In Table 1.1 a brief 
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summary of the four stages of drug development is shown. The drug discovery stage is used to 
investigate thousands of compounds by employing fast screening approaches, leading to a 
generation of lead compounds and then narrowing down the selection through targeted syn-
thesis and selective screening (lead optimization) (Lee and Kerns, 1999). This leads to a final 
selection of the most viable therapeutic candidates that are further characterized. In the pre-
clinical development stage, the characterization of the new drug substance is initiated, which 
includes preliminary information on stability, preparation, and control for manufacturing 
purposes (Kazakevich and LoBrutto, 2007). Stability of the new drug substance and drug 
products for at least 6 months is required. Appropriate data confirming the stereochemical 
homogeneity of the drug substance during stability studies, validation of analytical methods, 
and manufacture of the drug products are also required. Also at this stage appropriate bioana-
lytical methods are developed for the evaluation of pharmacokinetics, typically a series of studies 
focusing on absorption, distribution, metabolism and excretion (ADME) in animal species. 
Nowadays, most pharmaceutical companies are evaluating compounds for drug-like 
properties, such as solubility, lipophilicity and stability, at early stages in the discovery process, 
which allows identification of potential development challenges and thus the selection of the 
best candidates for lead optimization (Chen et al., 2006). The clinical development stage is 
constituted of three distinct phases (I-III). Each phase involves process scale-up, pharma-
cokinetics, drug delivery, and drug safety activities. In the manufacturing stage, the capabil-
ity for the production of large quantities of synthesized drug substance or drug product is 
ensured. Once formulated, the drug is packaged and prepared for distribution to pharmacy 
stores. Manufacturing processes and facilities undergo a preapproval regulatory review and 
periodic inspections once production is in progress. Analytical procedures and information 
databases are formalized into standard operating procedures (SOPs) and product specifica-
tions. This information and technology are formally transferred for routine monitoring and 
release by quality control (QC) scientists. During the manufacturing stage, comparisons are 
made to other drug products in the same category, including stability, bioavailability, and 
purity. Thus, comparative information is of interest during the transition from exclusive 
patent-protected drugs to the open generic market (Lee and Kerns, 1999). 
The stability property plays an important role in drug development and is one of the main 
topics of this thesis. Stability tests are performed based on guidelines issued by the Interna-
tional Conference on Harmonisation (ICH). The ICH is a unique project that connects the 
regulatory authorities of Europe, Japan and the USA as well as the experts from the pharma-
ceutical industry in these three regions. The main purpose is to create a more economical use 
of human, animal and material resources in quality, safety, efficacy, and multidisciplinary, or 
so called ‘Q’, ‘S’, ‘E’ and ‘M’ testing guidelines (ICH, 2010). The six co-sponsors of ICH are: (1) 
the Commission of the European Union; (2) the European Federation of Pharmaceutical In-
dustries’ Associations (EFPIA); (3) the Ministry of Health and Welfare, Japan (MHW); (4) the 
Japan Pharmaceutical Manufacturers Association (JPMA); (5) the US Food and Drug Admin-
istration (FDA); (6) the Pharmaceutical Research and Manufacturers of America (PhRMA). 
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The International Federation of Pharmaceutical Manufacturers Associations (IFPMA) par-
ticipates as an ‘umbrella’ organization for the pharmaceutical industry, providing the ICH 
secretariat. The World Health Organization (WHO), European Free Trade Association (EFTA) 
and Canada (represented by Health Canada) serve as observers to the ICH (Muller et al., 1999). 
ICH requires that a drug substance has to be tested under different stress conditions. It is 
suggested that stress testing includes the effect of pH, temperature, humidity, light and oxidiz-
ing agents. These tests are included in the guidelines Q1A (R2) “Stability Testing of New Drugs 
Substances and Products” and Q1B “Stability testing: Photostability Testing of New Drug 
Substances and Products”  (ICH, 2003, ICH, 1996b). 
Although the process to release a drug formulation needs to be in conformity with ICH 
norms, for many authors the guidelines do not provide detailed enough information with 
regard to: how to perform the stability assays (Brower et al., 1998, Christensen et al., 2000, 
Thatcher et al., 2001). Therefore, many reviews have been published to clarify the statements 
in the ICH guidelines (Baertschi et al., 2010, Bakshi and Singh, 2002, Ho and Chen, 1996, Ho 
and Chen, 1997). In these reviews the stability assays are explained with more details. The 
hydrolytic degradations are performed starting from 0.1 M of NaCl/NaOH under reflux. If no 
degradation is seen the drug should be refluxed under higher strength of acid/alkali and under 
longer duration. In a similar manner degradation under neutral conditions should be performed. 
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15
Chapter 1 General Introduction
To test for oxidation a concentration of 3% to 30% of hydrogen peroxide should be use. The 
photolytic studies should be carried out by exposure to light, using either a combination of 
cool white and ultraviolet fluorescent lamps, or one among the xenon and metal halide lamps. 
Samples should be submitted to wavelengths above 310 nm. This condition mimics the real 
environment of UV exposition to sun light, due to the fact that clouds and dust particles absorbs 
the lower wavelengths in the atmosphere (Anderson et al., 1991).
In order to generate high-quality data of stability studies, a specific, selective, robust and 
sensitive stability-indicating assay needs to be developed and validated. An ideal assay should 
allow detection of degradation peaks equivalent to 0.1% of the parent peak. Chromatography is 
the technique that is mainly used for stability studies. Other than separation of multiple com-
ponents, the advantage of chromatographic methods is that it possesses good accuracy and 
sensitivity for even small quantities of degradation products produced (Bakshi and Singh, 2002). 
Various chromatographic methods that have been used for stability assays include: thin-layer 
chromatography (TLC) (Bebawy et al., 2003, Mostafa, 2010, Youssef, 2005), high-performance 
thin-layer chromatography (HPTLC) (Kaul et al., 2004, Vadera et al., 2007, Venkatachalam and 
Chatterjee, 2007), gas chromatography (GC) (Avramides, 2005, Lima et al., 2005), HPLC (Fu et 
al., 2010, Kasawar and Farooqui, 2010, Naguib and Abdelkawy, 2010, Xiong et al., 2009), and 
capillary electrophoresis (CE) (Alnajjar et al., 2007, Baalbaki et al., 2005, Hamdam et al., 2010). 
More recently, huge attention is paid to genotoxic and carcinogenic effects of drugs, their 
degradation products and impurities. Genotoxicity tests can be defined as in vitro and in vivo 
tests designed to detect compounds that induce genetic damage by various mechanisms. 
Carcinogenicity tests are done mostly with drug substances that are used continuously for 6 
months or longer (ICH, 1995b). Guidelines for testing genotoxic and carcinogenic effects can 
be found in the guideline S2(R1): “Guidance on Genotoxicity Testing and Data Interpretation 
for Pharmaceuticals Intended for Human Use”(ICH, 2008b), and in S1A, “Guideline on the 
Need for Carcinogenicity Studies of Pharmaceuticals” (ICH, 1995a), S1B: “Testing for Carci-
nogenicity of Pharmaceuticals”(ICH, 1997a) and S1C(R2): “Dose Selection for Carcinogenic-
ity Studies of Pharmaceuticals”(ICH, 2008a). Performance of genotoxicity tests has improved 
over the years and the chances of failing to detect true genotoxic activity in a standard or ex-
tended battery of tests are small. Nevertheless, the area is still open for more sensitive, more 
practical, more expeditious, and more economical techniques for detection of genotoxic 
compounds (ICH, 1997b).
In parallel with toxicity tests, biochemical characterization of degradation compounds 
towards a specific target, in this case AChE, would be interesting to perform as degradation 
products could possibly provide new drug candidates for further investigation (Pleuvry, 2006, 
Tsuikiura et al., 1973). It is observed that not many stability studies pay attention to the bio-
chemical characterization of the formed degradation products.
This thesis provides stability assays based on the ICH guidelines of the anti-AD drugs tacrine, 
huperzine A, and galantamine. The three drugs have been subjected to various stress testing 
conditions (effect of pH, temperature, humidity, light and oxidizing agents) in order to study 
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degradation and degradation kinetics. In addition, structure elucidation of degradation products 
and bioactivity testing of the formed substances against AChE has been performed.
In Chapter 2, an overview of the current literature is presented regarding degradation studies, 
metabolism as well as bioanalysis of the anti-AD drugs that were used in the past and the ones 
that are in current use. In this chapter, more detailed information about these drugs is given, 
such as stability, methodologies used for their detection and quantification in different biologi-
cal matrices, and methods related to sample pretreatment. Moreover, the metabolism pathways 
of these drugs are also illustrated. The chapter is concluded by an overview about the most fre-
quently used sample pretreatment procedures and perspectives of future applications.
In Chapter 3, a stability study and an on-line AChE fluorescence based high-resolution 
screening (HRS) assay of the anti-AD drug tacrine is presented. The concept of HRS based 
assays is the integration of analytical separation with biochemical detection in an on-line setup. 
The effluent of the analytical column is first mixed with the protein under investigation (AChE) 
and subsequently, a substrate or a molecular probe is added. If no bioactive compound is eluting 
from the analytical column, the enzyme stays active and is for example continuously generating 
a fluorescent product from a non-fluorescent substrate. If a bioactive substance elutes from the 
analytical column and binds to the enzyme, the enzymatic activity is reduced, thereby giving a 
negative peak in the biochemical detection system. The detection methods used for HRS assays 
usually are based on ultraviolet (UV) (Ingkaninan et al., 2000), fluorescence (Marques et al., 
2010, Rhee et al., 2003), (laser induced) fluorescence (Heus et al., 2010) and mass spectrometry 
(MS) based (de Jong et al., 2006) detection. Fluorescence and MS based detection are most 
frequently applied because of their better sensitivity compared to UV detection. 
The assay formats depend on the drug target class which is incorporated (Kool et al., 2010). 
Some successful examples include: protein kinases (Falck et al., 2010), phosphatases (Schenk 
et al., 2003), proteases (Schebb et al., 2009) and drug metabolizing enzymes (Liempd et al., 
2005). In this thesis, a HRS system was applied for the screening of degradation products of 
tacrine in an on-line manner and to test their biological activity against AChE.
Stability assays showed that tacrine was basically stable under acidic and basic conditions 
as well as at elevated temperatures. Under hydrogen peroxide treatment, tacrine was de-
graded to a series of mono- di- and tri- hydroxylated compounds. These products were 
characterized chemically and biochemically and a comparison study with the metabolic pattern 
generated by P450 microsomal incubation was carried out. It was observed that some of the 
degradation products formed by P450 transformation were also formed under treatment with 
hydrogen peroxide. This was especially interesting as these compounds could be easily formed 
in batch amounts, thereby generating sufficient material for NMR analysis.
In Chapter 4, the stability of the anti-Alzheimer’s drug Huperzine A was studied. Huperzine 
A was found to be stable under all conditions, except under light exposure. Under irradiation 
with wavelengths above 310 nm, huperzine A showed transformation into an unknown substance, 
which is a new photoisomer of huperzine A, named photohuperzine A. The initial structure 
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elucidation step for the formed compound was triggered by the observation that the degradation 
product lost its UV absorption maximum at 308 nm (typical 2-pyridone absorption). MSn ex-
periments of the product did not give any insights into the structure of the degradation product, 
basically showing similar mass spectra to huperzine A. Hence, the compound was isolated and 
its structure was fully elucidated by using diverse NMR techniques (1H-NMR, 13C-NMR, COSY, 
HMBC, HSQC and NOESY), revealing a photoisomerization of the 2-pyridone ring of huperzine 
A. Interestingly, the compound showed a 100 times lower bioactivity against AChE than huper-
zine A itself, which proved that the planarity of the pyridone ring is important in the activity 
against AChE. Additionally, the kinetics of the photodegradation was investigated. 
In Chapter 5, a validated stability-indicating method for the anti-AD drug galantamine was 
developed. Galantamine was found to be stable only under alkaline conditions and at elevated 
temperatures. The degradation kinetics and the structure elucidation of the degradation 
compounds found under acidic, oxidative and photolytic conditions were achieved by MS and 
NMR (1H-NMR, 13C-NMR, COSY, HMBC, HSQC and NOESY) techniques. The isolated 
degradation products showed lower activity than the parent compound itself. In Chapter 6, 
the final conclusions and future perspectives of the work are given.
18
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